Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV

Virology

Volumn 435, Issue 1, 2013, Pages 81-91

  Chikere, Kelechi ^a   Chou, Tom ^a,b   Gorry, Paul R ^c,d,e   Lee, Benhur ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BURNET INSTITUTE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CCR5; CD4; Cellular tropism; Entry efficiency; Entry inhibitors; Env; HIV 1; Pathogenesis

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; CCR5 GENE; CD4 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; GENETIC CONSERVATION; HIGH THROUGHPUT SCREENING; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ISOLATION; VIRUS MUTATION; VIRUS VIRULENCE;

ANTIGENS, CD4; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL TROPISM; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870700527     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.09.043     Document Type: Review

References (64)

1. Agrawal-Gamse C., Lee F.H., Haggarty B., Jordan A.P., Yi Y., Lee B., Collman R.G., Hoxie J.A., Doms R.W., Laakso M.M. Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J. Virol. 2009, 83:11005-11015.
2. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., Sattentau Q.J., Schuitemaker H., Sodroski J., Weiss R.A. A new classification for HIV-1. Nature 1998, 391:240.
3. Berro R., Klasse P.J., Lascano D., Flegler A., Nagashima K.A., Sanders R.W., Sakmar T.P., Hope T.J., Moore J.P. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol. 2011, 85:8227-8240.
4. Bi S., Hong P.W., Lee B., Baum L.G. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10650-10655.
5. Blaak H., Ran L.J., Rientsma R., Schuitemaker H. Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. Virology 2000, 267:237-246.
6. Chesebro B., Buller R., Portis J., Wehrly K. Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J. Virol. 1990, 64:215-221.
7. Clapham P.R., Blanc D., Weiss R.A. Specific cell surface requirements for the infection of cd4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 1991, 181:703-715.
8. Colin D.M., Dejan L. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med. 2006, 3:e442.
9. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The cd4 (t4) antigen is an essential component of the receptor for the aids retrovirus. Nature 1984, 312:763-767.
10. Dejucq N., Simmons G., Clapham P.R. Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5. J. Virol. 1999, 73:7842-7847.
11. Duenas-Decamp M.J., Peters P.J., Repik A., Musich T., Gonzalez-Perez M.P., Caron C., Brown R., Ball J., Clapham P.R. Variation in the biological properties of HIV-1 R5 envelopes. implications of envelope structure, transmission and pathogenesis. Future Virol. 2010, 5:435-451.
12. Gorry P.R., Ancuta P. Coreceptors and HIV-1 pathogenesis. Curr. HIV/AIDS Rep. 2011, 8:45-53.
13. Gorry P.R., Taylor J., Holm G.H., Mehle A., Morgan T., Cayabyab M., Farzan M., Wang H., Bell J.E., Kunstman K., Moore J.P., Wolinsky S.M., Gabuzda D. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 2002, 76:6277-6292.
14. Gray L., Sterjovski J., Churchill M., Ellery P., Nasr N., Lewin S.R., Crowe S.M., Wesselingh S.L., Cunningham A.L., Gorry P.R. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005, 337:384-398.
15. Jiang C., Parrish N.F., Wilen C.B., Li H., Chen Y., Pavlicek J.W., Berg A., Lu X., Song H., Tilton J.C., Pfaff J.M., Henning E.A., Decker J.M., Moody M.A., Drinker M.S., Schutte R., Freel S., Tomaras G.D., Nedellec R., Mosier D.E., Haynes B.F., Shaw G.M., Hahn B.H., Doms R.W., Gao F. Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J. Virol. 2011, 85:10669-10681.
16. Johnston S.H., Lobritz M.A., Nguyen S., Lassen K., Delair S., Posta F., Bryson Y.J., Arts E.J., Chou T., Lee B. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 2009, 83:11016-11026.
17. Kikukawa R., Koyanagi Y., Harada S., Kobayashi N., Hatanaka M., Yamamoto N. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J. Virol. 1986, 57:1159-1162.
18. Kimata J.T., Gosink J.J., KewalRamani V.N., Rudensey L.M., Littman D.R., Overbaugh J. Coreceptor specificity of temporal variants of simian immunodeficiency virus mne. J. Virol. 1999, 73:1655-1660.
19. Kimata J.T., Kuller L., Anderson D.B., Dailey P., Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 1999, 5:535-541.
20. Klatzmann D., Barre-Sinoussi F., Nugeyre M.T., Danquet C., Vilmer E., Griscelli C., Brun-Veziret F., Rouzioux C., Gluckman J.C., Chermann J.C., et al. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 1984, 225:59-63.
21. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J.C., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
22. Koning F.A., Kwa D., Boeser-Nunnink B., Dekker J., Vingerhoed J., Hiemstra H., Schuitemaker H. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 2003, 188:864-872.
23. Kozak S.L., Platt E.J., Madani N., Ferro F.E., Peden K., Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 1997, 71:873-882.
24. Kwa D., Vingerhoed J., Boeser B., Schuitemaker H. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J. Infect. Dis. 2003, 187:1397-1403.
25. Lassen K.G., Lobritz M.A., Bailey J.R., Johnston S., Nguyen S., Lee B., Chou T., Siliciano R.F., Markowitz M., Arts E.J. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog. 2009, 5:e1000377.
26. Lee, B., Doms, R.W., 2001. Quantification of HIV SIV Coreceptor Expression. John Wiley and Sons, Inc. pp. 53-66 (Chapter 4).
27. Li S., Juarez J., Alali M., Dwyer D., Collman R., Cunningham A., Naif H.M. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J. Virol. 1999, 73:9741-9755.
28. Liang M., Morizono K., Pariente N., Kamata M., Lee B., Chen I.S. Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway. J. Virol. 2009, 83:13026-13031.
29. Lin N.H., Kuritzkes D.R. Tropism testing in the clinical management of HIV-1 infection. Curr. Opin. HIV AIDS 2009, 4:481-487.
30. Liu, S., Aliyari, R., Chikere, K., Marsden, M., Li, G., Wang, Y., Su, L., Zack, J., Freiberg, A., Lee, B., Cheng, G. The interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity, in press.
31. Lobritz M.A., Marozsan A.J., Troyer R.M., Arts E.J. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J. Virol. 2007, 81:8258-8269.
32. Loftin L.M., Kienzle M.F., Yi Y., Lee B., Lee F.H., Gray L., Gorry P.R., Collman R.G. Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1. efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology 2010, 402:135-148.
33. Marozsan A.J., Moore D.M., Lobritz M.A., Fraundorf E., Abraha A., Reeves J.D., Arts E.J. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J. Virol. 2005, 79:7121-7134.
34. Melikyan G.B. Common principles and intermediates of viral protein-mediated fusion. the HIV-1 paradigm. Retrovirology 2008, 5:111.
35. Nedellec R., Coetzer M., Shimizu N., Hoshino H., Polonis V., Morris L., Märtensson U., Binley J., Overbaugh J., Mosier D. Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J. Virol. 2009, 83:8353-8363.
36. Olivieri K., Scoggins R.M., Bor Y.C., Matthews A., Mark D., Taylor J.R., Chernauskas D., Hammarskjold M.L., Rekosh D., Camerini D. The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. Virology 2007, 358:23-38.
37. Pakarasang M., Wasi C., Suwanagool S., Chalermchockcharoenkit A., Auewarakul P. Increased HIV-DNA load in CCR5-negative lymphocytes without viral phenotypic change. Virology 2006, 347:372-378.
38. Pastore C., Ramos A., Mosier D.E. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J. Virol. 2004, 78:7565-7574.
39. Peters P., Dueñas-Decamp M., Sullivan W., Clapham P. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J. NeuroImmune Pharmacol. 2007, 2:32-41.
40. Pfaff J.M., Wilen C.B., Harrison J.E., Demarest J.F., Lee B., Doms R.W., Tilton J.C. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J. Virol. 2010, 84:6505-6514.
41. Platt E.J., Madani N., Kozak S.L., Kabat D. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J. Virol. 1997, 71:883-890.
42. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
43. Pugach P., Ray N., Klasse P., Ketas T., Michael E., Doms R., Lee B., Moore J. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 2009, 387:296-302.
44. Rangel H.R., Weber J., Chakraborty B., Gutierrez A., Marotta M.L., Mirza M., Kiser P., Martinez M.A., Este J.A., Quinones-Mateu M.E. Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J. Virol. 2003, 77:9069-9073.
45. Roche M., Jakobsen M.R., Ellett A., Salimiseyedabad H., Jubb B., Westby M., Lee B., Lewin S.R., Churchill M.J., Gorry P.R. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology 2011, 8:89.
46. Roche M., Jakobsen M.R., Sterjovski J., Ellett A., Posta F., Lee B., Jubb B., Westby M., Lewin S.R., Ramsland P.A., Churchill M.J., Gorry P.R. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J. Virol. 2011, 85:4330-4342.
47. Saez E., Nelson M.C., Eshelman B., Banayo E., Koder A., Cho G.J., Evans R.M. Identification of ligands and coligands for the ecdysone-regulated gene switch. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:14512-14517.
48. Salimi, H., Roche, M., Webb, N., Gray, L., Chikere, K., Sterjovski, J., Ellett, A., Wesselingh, S., Ramsland, P., Lee, B., Churchill, M., Gorry, P.R., Macrophage -tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. Journal of Leukocyte Biology, , in press. http://dx.doi.org/10.1189/jlb.0612308.
49. Sato S., Ouellet M., St-Pierre C., Tremblay M.J. Glycans, galectins, and HIV-1 infection. Ann. N.Y. Acad. Sci. 2012, 1253:133-148.
50. Schnell G., Joseph S., Spudich S., Price R.W., Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 2011, 7:e1002286.
51. Smit T.K., Wang B., Ng T., Osborne R., Brew B., Saksena N.K. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC). evidence for neurotropic HIV variants. Virology 2001, 279:509-526.
52. St-Pierre C., Manya H., Ouellet M., Clark G.F., Endo T., Tremblay M.J., Sato S. Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4. J. Virol. 2011, 85:11742-11751.
53. St-Pierre C., Ouellet M., Tremblay M.J., Sato S. Galectin-1 and HIV-1 infection. Methods Enzymol. 2010, 480:267-294.
54. Sterjovski J., Roche M., Churchill M.J., Ellett A., Farrugia W., Gray L.R., Cowley D., Poumbourios P., Lee B., Wesselingh S.L., Cunningham A.L., Ramsland P.A., Gorry P.R. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology 2010, 404:269-278.
55. Tilton J.C., Wilen C.B., Didigu C.A., Sinha R., Harrison J.E., Agrawal-Gamse C., Henning E.A., Bushman F.D., Martin J.N., Deeks S.G., Doms R.W. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 2010, 84:10863-10876.
56. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
57. Tuttle D.L., Anders C.B., Aquino-De Jesus M.J., Poole P.P., Lamers S.L., Briggs D.R., Pomeroy S.M., Alexander L., Peden K.W., Andiman W.A., Sleasman J.W., Goodenow M.M. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res. Hum. Retroviruses 2002, 18:353-362.
58. UNAIDS, 2008, 2008 Report on the Global AIDS Epidemic. Geneva, Switzerland.
59. Westby M. Resistance to CCR5 antagonists. Curr. Opin. HIV AIDS 2007, 2:137-144.
60. Wilen C.B., Tilton J.C., Doms R.W. HIV. cell binding and entry. Cold Spring Harb. Perspect. Med. 2012, 2.
61. Wilen C.B., Tilton J.C., Doms R.W. Molecular mechanisms of HIV entry. Adv. Exp. Med. Biol. 2012, 726:223-242.
62. Wilkin T.J., Gulick R.M. CCR5 antagonism in HIV infection. current concepts and future opportunities. Annu. Rev. Med. 2012, 63:81-93.
63. Wyatt R., Sullivan N., Thali M., Repke H., Ho D., Robinson J., Posner M., Sodroski J. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 1993, 67:4557-4565.
64. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 2010, 10:527-535.